Pharmaceutical Portfolio Development Strategic Rationale Challenges Internal innovation costs approximately $2b to bring a single pharmaceutical biotechnology product to market. other studies have included time costs, i.e. expected returns that investors forego while a drug is in development, and costs for post approval studies, which bring the total estimate. Through cases based on the author’s engagements, this article highlights common challenges and creative solutions that lead to the development and execution of viable portfolio strategies.
Decision Making In Product Portfolios Of Pharmaceutical Research And The article discusses the importance of a strategic portfolio approach in the biopharmaceutical industry to achieve revenue growth and manage risks associated with drug development. Through cases based on the author’s engagements, this article highlights common challenges and creative solutions that lead to the development and execution of viable portfolio strategies implemented by firms of diverse sizes and corporate objectives. Effective portfolio management is crucial for innovation and sustaining revenue in pharmaceutical companies. this article holistically reviews trends, challenges, and approaches to pharmaceutical portfolio management and focuses, in particular, on cognitive biases in portfolio decision making. Leading biopharmaceutical companies manage their clinical pipelines to optimize for risk and reward. here’s how. discovering and developing effective new medicines has always been difficult—but it is particularly hard today.
Challenges Of Pharmaceutical Industry Key Issues In 2025 Effective portfolio management is crucial for innovation and sustaining revenue in pharmaceutical companies. this article holistically reviews trends, challenges, and approaches to pharmaceutical portfolio management and focuses, in particular, on cognitive biases in portfolio decision making. Leading biopharmaceutical companies manage their clinical pipelines to optimize for risk and reward. here’s how. discovering and developing effective new medicines has always been difficult—but it is particularly hard today. The decisions that most directly improve pots (biomarker strategy, adaptive design, indication selection) are made in early clinical development, not at phase iii, which is why portfolio strategy must engage r&d at the ind stage rather than waiting for phase iib readouts. Marketed drugs will decrease, leaving a substantial gap to be filled to achieve the desired revenue target. the company will now explore strategies of adding new projects to the development portfolio,. The increasing costs and complexity of r&d in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage. While the market continues to expand, several structural challenges hinder equitable access and sustainability. among these are the high costs of drug development, the concentration of api manufacturing in select countries such as china.
Key Regulatory Challenges In Pharmaceutical Development Global The decisions that most directly improve pots (biomarker strategy, adaptive design, indication selection) are made in early clinical development, not at phase iii, which is why portfolio strategy must engage r&d at the ind stage rather than waiting for phase iib readouts. Marketed drugs will decrease, leaving a substantial gap to be filled to achieve the desired revenue target. the company will now explore strategies of adding new projects to the development portfolio,. The increasing costs and complexity of r&d in the pharmaceutical industry have necessitated the adoption of strategic portfolio management to optimize resource allocation and enhance competitive advantage. While the market continues to expand, several structural challenges hinder equitable access and sustainability. among these are the high costs of drug development, the concentration of api manufacturing in select countries such as china.
Comments are closed.